ASMS

MOBILion to Showcase Innovations in Separation Science - New Capabilities and Application Workflows at ASMS 2023

Retrieved on: 
Thursday, June 1, 2023
PTM, American Society for Mass Spectrometry, Structure, Glycoprotein, PFAS, ASMS, SLIM, Lipidomics, Mass spectrometry, Software, Booth, Lipid, Thermo Fisher Scientific, Doctor of Philosophy, Excipient, MOBIE, PerkinElmer, Agilent Technologies, Protein, LCMS, Lactoferrin, Poster, Society, Structures for lossless ion manipulations, Citrullination, Peptide, Orbitrap, Fine chemical

MOBILion's high-resolution ion mobility product, MOBIE®, provides the industry's highest resolution, full mass range, single pass ion mobility separation capability.

Key Points: 
  • MOBILion's high-resolution ion mobility product, MOBIE®, provides the industry's highest resolution, full mass range, single pass ion mobility separation capability.
  • In six seminar presentations, industry collaborators will present data demonstrating the unique ability to solve their analytical challenges with high-resolution ion mobility (HRIM-MS).
  • ASMS provides the perfect venue to share our latest advancements and foster collaborations that will drive innovation forward."
  • To obtain further details regarding MOBILion Systems' presence at ASMS 2023 and to register for the events, please visit: https://info.mobilionsystems.com/asms2023 .

Biognosys Launches Spectronaut 18 and Presents Advances in Proteomics Depth, Sensitivity, and Scalability at the ASMS 2023 Annual Conference

Retrieved on: 
Wednesday, May 31, 2023
Scripps Research, American Society for Mass Spectrometry, Partnership, QC, ASMS, Urine, Workflow, Mass spectrometry, CDK, Proteome, Cerebrospinal fluid, Proteomics, Full, Cooperative Human Tissue Network, Plasma, IRT, Protein, AbbVie, Drug discovery, CCS, Peptide, DIA, Society, Conference, Tissue, Automation, Software, Video game, Fine chemical, Bruker

Biognosys’ scientific presence includes a breakfast seminar introducing Spectronaut 18, along with three oral presentations and nine posters.

Key Points: 
  • Biognosys’ scientific presence includes a breakfast seminar introducing Spectronaut 18, along with three oral presentations and nine posters.
  • “Our continuous commitment to innovation in mass spectrometry-based proteomics is once again emphasized by our significant contribution to the ASMS scientific program,” said Lukas Reiter, Ph.D., Chief Technology Officer of Biognosys.
  • A major launch arising from the strategic partnership is the combination of Biognosys’ iRT kit together with the Bruker ProteoScape™ product.
  • Biognosys will launch the latest version of Spectronaut during their Monday, June 5, breakfast seminar “Spectronaut 18: Limitless Throughput.

908 Devices Features its High-Speed, High-Resolution Separations Technology at the 71st ASMS Conference

Retrieved on: 
Tuesday, May 30, 2023
Technology, Medical Devices, General Health, Science, Biotechnology, Health, Health Technology, Other Science, Research, Other Technology, Nanotechnology, Biometrics, Other Health, Mobile, Wireless, Hardware, Pharmaceutical, Consumer Electronics, Peptide, CE, Duke University, University, CPI, ASMS, Workflow, Mass spectrometry, Hook effect, Weizmann Institute of Science, Bruker, University of Connecticut, RNA, TrafFix Devices, Inc. v. Marketing Displays, Inc., Thermo Fisher Scientific, Dicarboxylic acid, AAV, Proteomics, Protein, Vivisection, University of Wisconsin–Madison, MASS, Regeneron Pharmaceuticals, Therapy, Oligonucleotide, Conference, Medical device

908 Devices is revolutionizing chemical and biochemical analysis with its mass spec devices that are simple to operate, provide answers in minutes and are used at the point of need.

Key Points: 
  • 908 Devices is revolutionizing chemical and biochemical analysis with its mass spec devices that are simple to operate, provide answers in minutes and are used at the point of need.
  • He will also discuss ZipChip’s key advantages such as versatility, high sensitivity, short analysis times and lack of method development.
  • 908 Devices will exhibit its handheld and desktop devices in booth #603 at ASMS.
  • To see a complete list of posters the company is presenting with its collaborators and to register for the breakfast seminar, visit www.908devices.com/asms .

MOBILion Systems to Expand Applications of SLIM Separation Technology with License to TOFWERK AG

Retrieved on: 
Thursday, May 18, 2023
American Society for Mass Spectrometry, Aerosol, ASMS, SLIM, Mass spectrometry, Gas, Organic compound, Structures for lossless ion manipulations, Volatile organic compound, Unresolved complex mixture, LC-MS, Instrumental chemistry, Society

CHADDS FORD, Pa., May 18, 2023 /PRNewswire/ -- MOBILion Systems Inc. and Thun, Switzerland-based TOFWERK AG have announced a sublicensing agreement for the development of an ion mobility/time-of-flight (TOF) mass spectrometry product based on Structures for Lossless Ion Manipulation (SLIM) separation technology.

Key Points: 
  • CHADDS FORD, Pa., May 18, 2023 /PRNewswire/ -- MOBILion Systems Inc. and Thun, Switzerland-based TOFWERK AG have announced a sublicensing agreement for the development of an ion mobility/time-of-flight (TOF) mass spectrometry product based on Structures for Lossless Ion Manipulation (SLIM) separation technology.
  • TOFWERK provides innovative solutions for chemical analysis, developing time-of-flight mass spectrometers for applications that demand exceptional speed and sensitivity.
  • "We are excited to be able to expand applications and continue to demonstrate the impact of the SLIM platform technology more broadly.
  • TOFWERK's expertise in this market will accelerate the implementation of the SLIM technology to address customers' needs in volatile compound analysis."

Viva Biotech's Recent Conferences & Events Review

Retrieved on: 
Friday, May 5, 2023
Molecule, Dai, GMP, Communication, SAPA, Senior, ASMS, Marketing, Development, Journal, Patient, Environment, EHS, Science, Friends, Synthesis, Attention, Production, A39, CDE, Drug discovery, PCSK9, CIO, FDA, Conference, NMPA, BD, D, Medicinal chemistry, PROTAC, Intellectual property, AACR, Exhibition, SPR, Challenge, API, Parlour, American Association for Cancer Research, PDT, Biomedicine, Forum, Synthetic biology, Factorization of polynomials, Drug development, MOA, CMC, Booth, NDA, EDT, CDMO, Estate (law), Artificial intelligence, Fine chemical, Pharmaceutical industry, Medical device, Bioassay, IND

Experts shared a lot of great contents and idea in these conferences and events.

Key Points: 
  • Experts shared a lot of great contents and idea in these conferences and events.
  • As one of the key players in innovative drug discovery CRO, Viva has served thousands of global innovative drug development clients in the past decade.
  • He believes that in the future, Viva Biotech can empower more domestic innovative drug companies and help them achieve internationalization in original drug research.
  • Viva would continue to strengthen one-stop drug development and manufacturing service platform to better empower the development of biopharmaceutical innovation.

Frontier Airlines Reports First Quarter 2023 Financial Results with Spring Break Outperforming Expectations

Retrieved on: 
Wednesday, May 3, 2023
Airbus A320neo family, Airbus, GAAP, ASMS, Risk, Airbus A320 family, Airline, Medical device, Frontier

During the first quarter of 2023, Frontier generated 104 ASMs per gallon.

Key Points: 
  • During the first quarter of 2023, Frontier generated 104 ASMs per gallon.
  • The A321neo is expected to unlock meaningful scale efficiencies by way of fuel savings and higher average seats per departure.
  • As of March 31, 2023, approximately 70 percent of future committed aircraft deliveries, including direct leases, are for A321neo aircraft.
  • The effective tax rate for both the second quarter and full-year 2023 is estimated to be approximately 24 percent.

Sun Country Airlines Reports First Quarter 2023 Results

Retrieved on: 
Thursday, April 27, 2023
Pressure, Apollo Global Management, ASMS, Share repurchase, Multimedia Class Scheduler Service, Airport, Income tax, Woman, GAAP, Oman Air, Amazon, Sun Country Airlines, CASM, Growth, Aircraft, Video game, Airline

MINNEAPOLIS, April 27, 2023 (GLOBE NEWSWIRE) -- Sun Country Airlines Holdings, Inc. (“Sun Country Airlines,” “Sun Country,” the “Company”) (NASDAQ: SNCY) today reported financial results for its first quarter ended March 31, 2023.

Key Points: 
  • For the first quarter of 2023, the Company reported total revenue of $294 million, which was 29.8% more than the first quarter of 2022.
  • The first quarter 2023 average total fare of $221 exceeded first quarter 2022 by 20.8% and included strong average ancillary revenue per passenger of $69.
  • On a rate basis, first quarter 2023 charter revenue per block hour was 5.7% higher than the rate in the first quarter of 2022.
  • In the first quarter of 2023, cargo revenue was $23 million, a 11.0% increase versus the first quarter of 2022.

Latest XCOPRI® (cenobamate tablets) CV Post-hoc Analysis Presented at the 75th American Academy of Neurology Annual Meeting

Retrieved on: 
Monday, April 17, 2023
Epilepsy, Seizure, Abstract, Maintenance, Medical Affairs Bureau, Central nervous system, CV, ASMS, AAN, Grenfell Tower Inquiry Phase 2, Cenobamate, ASM, American Academy, MBA, CNS, Pharmacist, Death, MD, Patient, Annual general meeting, FAES, Mortality, American Academy of Neurology, FAAN, SUDEP, Pharmaceutical industry

The data includes post-hoc analyses on the rate of SUDEP and drug load in adults with partial-onset (focal) seizures taking XCOPRI® (cenobamate tablets) CV.

Key Points: 
  • The data includes post-hoc analyses on the rate of SUDEP and drug load in adults with partial-onset (focal) seizures taking XCOPRI® (cenobamate tablets) CV.
  • For people with epilepsy, the all-cause mortality rate is typically higher than the general population, with one factor being SUDEP.
  • For those with drug resistant epilepsy, the SUDEP rate increases to as high as 9.3 deaths per 1,000 person years.
  • All abstracts being presented at AAN, including the ten being presented by SK Life Science, can be found here and also at booth #2091.

Delta Air Lines Announces March Quarter 2023 Financial Results

Retrieved on: 
Thursday, April 13, 2023
Kansas City metropolitan area, Delta Air Lines, S&P, Partnership, Travel, International, Medium term note, ASMS, The Wall Street Journal, American Express, Aviation, Unit, JFK, Philosophy, SkyMiles, DOT, Elizabeth City State University, Atmosphere of Earth, Investment, Semiconductor Manufacturing International Corporation, Corporation, Janki, CASM, Growth, A14, Pratt & Whitney PW1000G, Wine, MRO, Delta one, Airline, Video game, Renewable energy, Security (finance), Hertz, Premium, Delta, Fitch

ATLANTA, April 13, 2023 /PRNewswire/ -- Delta Air Lines (NYSE:DAL) today reported financial results for the March quarter and provided its outlook for the June quarter 2023.  Highlights of the March quarter, including both GAAP and adjusted metrics, are on page five and incorporated here.

Key Points: 
  • These results reflect the strength in the underlying demand environment and continued momentum in premium products and loyalty revenue," said Glen Hauenstein, Delta's president.
  • Unit revenue strength continues, driven by consumer: Reflecting strong demand, March quarter advance cash bookings were nearly 20 percent higher than 2019.
  • March quarter adjusted total unit revenue (TRASM) was up 16 percent versus 2019 and 23 percent higher versus 2022.
  • Recent corporate survey results indicate that 96 percent of companies expect their travel will increase or stay the same sequentially in the June quarter.

Viva Biotech Attended SAPA-China

Retrieved on: 
Thursday, April 13, 2023
Medicinal chemistry, Science, Intellectual property, SAPA, MOA, Senior, Exhibition, ASMS, SPR, Challenge, Under-occupied developments in China, Development, Journal, Patient, PCSK9, Conference, Synthetic biology, Fine chemical

Viva Biotech was invited to participate in this annual conference, and Dr. Jianhua Cai, Senior Vice President of Viva Biotech, and Dr. Jianguo Ma, Senior Vice President of Viva Biotech and CEO of Langhua Pharmaceutical, were invited as guest speakers in the keynote speeches.

Key Points: 
  • Viva Biotech was invited to participate in this annual conference, and Dr. Jianhua Cai, Senior Vice President of Viva Biotech, and Dr. Jianguo Ma, Senior Vice President of Viva Biotech and CEO of Langhua Pharmaceutical, were invited as guest speakers in the keynote speeches.
  • As one of the key players in innovative drug discovery CRO, Viva has served thousands of global innovative drug development clients in the past decade.
  • He believes that in the future, Viva Biotech can empower more domestic innovative drug companies and help them achieve internationalization in original drug research.
  • At SAPA-CHINA, Viva Biotech fully demonstrated its one-stop platform for early-stage structure-based drug discovery to commercial drug delivery, as well as multiple core technologies and successful cases such as protein production and preparation, structural biology, cryo-EM, drug screening, Bioassay, medicinal chemistry, computer-aided drug design, etc.